ASSOCIATION OF TUMORIGENIC AND NONTUMORIGENIC (IMMUNOGENIC) VARIANTS IN A MOUSE T-CELL LYMPHOMA WITH 2 DISTINCT P53 MUTATIONS

被引:9
作者
BERGEL, M
BHATIA, K
SIWARSKI, D
GUTIERREZ, M
HOCHMAN, J
HUPPI, K
机构
[1] NCI,MOLEC GENET SECT,GENET LAB,BETHESDA,MD 20892
[2] HEBREW UNIV JERUSALEM,DEPT CELL & ANIM BIOL,JERUSALEM,ISRAEL
[3] NCI,PEDIAT BRANCH,CLIN ONCOL PROGRAM,BETHESDA,MD
关键词
P53; MUTATION; SINGLE-STRAND CONFORMATION POLYMORPHISM;
D O I
10.1002/mc.2940080404
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An in vitro model system for xenogenization has been developed in which an immunogenic, nonmalignant phenotype was selected from a highly malignant T-cell line (S49). We showed by single-strand conformation polymorphism and DNA sequence analysis that specific point mutations in the p53tumor suppressor gene correlated with a change from a tumorigenic a nontumorigenic (immunogenic) phenotype. Specifically, we found that the highly malignant S49 cell line T-60 contains an Arg-->Gln substitution at residue 246 in exon 7 of p53. In contrast, nontumorigenic (immunogenic) variants (T-25-Adh and Rev-1) exhibited a Gly-->Ser substitution at residue 242 of p53. In two subsequent tumorigenic revertants derived from Rev-1, we again found the Arg-->Gln substitution at residue 246 that was found initially in the T-60 cells. Thus, mutation at residue 246 of p53 was associated with a highly malignant phenotype, whereas a novel mutation at residue 242 of p53 appeared to be associated with a nonmalignant phenotype and may have actually protected the host through immunization. We conclude that mutation of residue 242 may represent a new class of permissive (nonmalignant) mutations in the mouse that are analogous to the Li-Fraumeni mutation in humans. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 25 条
  • [1] CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS
    BAKER, SJ
    FEARON, ER
    NIGRO, JM
    HAMILTON, SR
    PREISINGER, AC
    JESSUP, JM
    VANTUINEN, P
    LEDBETTER, DH
    BARKER, DF
    NAKAMURA, Y
    WHITE, R
    VOGELSTEIN, B
    [J]. SCIENCE, 1989, 244 (4901) : 217 - 221
  • [2] BHATIA KG, 1992, CANCER RES, V52, P4273
  • [3] ANALYSIS OF THE GENE CODING FOR THE MURINE CELLULAR TUMOR-ANTIGEN P53
    BIENZ, B
    ZAKUTHOURI, R
    GIVOL, D
    OREN, M
    [J]. EMBO JOURNAL, 1984, 3 (09) : 2179 - 2183
  • [4] A ROLE FOR SUNLIGHT IN SKIN-CANCER - UV-INDUCED P53 MUTATIONS IN SQUAMOUS-CELL CARCINOMA
    BRASH, DE
    RUDOLPH, JA
    SIMON, JA
    LIN, A
    MCKENNA, GJ
    BADEN, HP
    HALPERIN, AJ
    PONTEN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) : 10124 - 10128
  • [5] DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1
  • [6] WILD-TYPE P53 CAN INHIBIT ONCOGENE-MEDIATED FOCUS FORMATION
    ELIYAHU, D
    MICHALOVITZ, D
    ELIYAHU, S
    PINHASIKIMHI, O
    OREN, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) : 8763 - 8767
  • [7] THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION
    FINLAY, CA
    HINDS, PW
    LEVINE, AJ
    [J]. CELL, 1989, 57 (07) : 1083 - 1093
  • [8] GUTIERREZ MI, 1992, CANCER RES, V52, P1032
  • [9] HALEVY O, 1991, ONCOGENE, V6, P1593
  • [10] CELL ADHESIVENESS IS RELATED TO TUMORIGENICITY IN MALIGNANT LYMPHOID-CELLS
    HOCHMAN, J
    LEVY, E
    MADOR, N
    GOTTESMAN, MM
    SHEARER, GM
    OKON, E
    [J]. JOURNAL OF CELL BIOLOGY, 1984, 99 (04) : 1282 - 1288